ResMed Inc
RMD
Company Profile
Business description
ResMed makes continuous positive airway pressure devices and the masks used to treat obstructive sleep apnea, a condition in which the airway repeatedly collapses during sleep. Devices make up about half of revenue, masks and accessories close to 40%, and residential care software the remainder. Growth depends on diagnosing more of the large untreated sleep apnea population and moving them onto therapy. The Americas contribute about two-thirds of device and mask revenue, with most of the rest from Europe, Japan, and Australia.
Contact
9001 Spectrum Center Boulevard
San DiegoCA92123
USAT: +1 858 836-5000
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
30 June 2027
Employees
11,370
ResMed Inc News & Analysis
stocks
Weight loss drugs not an existential threat to undervalued ASX share
A durable growth story despite GLP-1 headwinds.
stocks
Solid quarter for undervalued ASX listed share
Solid global sales and margin expansion are highlights from latest quarter.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,025.40 | 12.80 | 0.14% |
| CAC 40 | 7,983.26 | 13.26 | 0.17% |
| DAX 40 | 25,891.56 | 148.12 | -0.57% |
| Dow JONES (US) | 52,342.56 | 132.54 | -0.25% |
| FTSE 100 | 10,749.88 | 27.81 | 0.26% |
| HKSE | 23,294.42 | 335.77 | 1.46% |
| NASDAQ | 26,184.72 | 365.13 | -1.38% |
| Nikkei 225 | 63,290.11 | 1,369.36 | -2.12% |
| NZX 50 Index | 13,797.00 | 86.83 | 0.63% |
| S&P 500 | 7,720.39 | 23.59 | -0.30% |
| S&P/ASX 200 | 8,908.10 | 16.30 | 0.18% |
| SSE Composite Index | 3,599.02 | 52.42 | -1.44% |